Table 1.
Ongoing clinical trials with antibodies directed against PD-1/PD-L1 to treat breast cancer
| Antibody | Target | Study identifier (study name) | Phase | Breast cancer subtype | Combination with |
|---|---|---|---|---|---|
| Pembrolizumab | PD-1 | NCT02555657 | III | advanced TN | |
| (MK3475) | PD-L1 | (KEYNOTE-119) | |||
| NCT02555657 | advanced TN | mono-CTX | |||
| (KEYNOTE-355) | |||||
| Atezolizumab | NCT02425891 | advanced TN | nab-paclitaxel | ||
| (MPDL3280A) | (IMpassion) | ||||
| Pembrolizumab | PD-1 | NCT02648477 | II | advanced HER2+ | doxorubicin/aromatase |
| (MK3475) | inhibitor | ||||
| NCT02447003 | advanced TN | ||||
| (KEYNOTE-086) | |||||
| NCT02752685 | advanced HER2− | nab-paclitaxel | |||
| NCT02644369 | advanced TN | ||||
| (INSPIRE) | |||||
| Atezolizumab | PD-L1 | NCT02530489 | neoadjuvant TN | nab-paclitaxel | |
| (MPDL3280A) | (TN first line) | ||||
| Durvalumab | PD-L1 | NCT02669914 | brain metastases | ||
| (MEDI4736) | NCT02536794 | advanced HER2− | tremelilumab | ||
| NCT02685059 | neoadjuvant TN | neoadjuvant CTX | |||
| (GeparNuevo) | |||||
| PDR001 | PD-1 | NCT02404441 | I–II | advanced TN | |
| NCT02404441 | advanced TN | ||||
| Pembrolizumab | PD-1 | NCT02129556 | advanced HER2+ | trastuzumab | |
| (MK3475) | (PANACEA) | ||||
| NCT02657889 | advanced TN | mono-CTX | |||
| (KEYNOTE-162) | |||||
| NCT02513472 | advanced TN | eribulin | |||
| NCT02452424 | advanced TN | PLX3397 | |||
| Atezolizumab | PD-L1 | NCT02543645 | advanced TN | varlilumab | |
| (MPDL3280A) | NCT02708680 | advanced TN | entinostat | ||
| Avelumab | PD-L1 | NCT02554812 | advanced TN | PF-05082566, PF-04518600 | |
| (MSB0010718C) | |||||
| Durvalumab | PD-L1 | NCT02484404 | advanced TN | olaparib/cediranib | |
| (MEDI4736) | NCT02734004 | advanced | olaparib | ||
| gBRCA+/HER2− | |||||
| NCT02489448 | neoadjuvant TN | neoadjuvant CTX | |||
| Nivolumab | PD-1 | NCT02309177 | I | advanced HER- | nab-paclitaxel |
| (BMS-936558) | |||||
| Pembrolizumab | PD-1 | NCT02622074 | neoadjuvant TN | neoadjuvant CTX | |
| (MK3475) | (KEYNOTE-172) | ||||
| NCT01975831 | advanced non-TN | tremelilumab | |||
| NCT02622074 | neoadjuvant TN | neoadjuvant CTX | |||
| (KEYNOTE-173) | |||||
| NCT02452424 | advanced TN | enoblituzumab | |||
| Atezolizumab | PD-L1 | NCT01375842 | advanced | ||
| (MPDL3280A) | NCT02605915 | advanced HER2+ | trastuzumab + | ||
| pertuzumab/T-DM1 | |||||
| Avelumab | PD-L1 | NCT01772004 | advanced | ||
| (MSB0010718C) | |||||
| Durvalumab | PD-L1 | NCT02628132 | advanced TN | paclitaxel | |
| (MEDI4736) | NCT02649686 | advanced HER2+ | trastuzumab | ||
TN = Triple negative, HER2 = human epidermal growth factor receptor 2, gBRCA = germline BRCA CTX = chemotherapy, nab-paclitaxel = nanoparticle albumin-bound paclitaxel, T-DM1 = trastuzumab-emtansin.